| Gene symbol | KRT31 | Synonyms | HA1, Ha-1, KRTHA1, hHa1 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
| Description | keratin 31 | ||||
| Gene symbol | KRT32 | Synonyms | HA2, HKA2, KRTHA2, hHa2 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
| Description | keratin 32 | ||||
| GTO ID | GTC3131 |
| Trial ID | NCT05473910 |
| Disease | Myelodysplastic Syndrome | Leukemia |
| Altered gene | HA1|HA2 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TSC-100|TSC-101 |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation |
| Year | 2022 |
| Country | United States |
| Company sponsor | TScan Therapeutics, Inc. |
| Other ID(s) | TSCAN-001 |
| Cohort1: HA-1 positive | |||||||||
|
|||||||||
| Cohort2: HA-2 positive | |||||||||
|
|||||||||